ARVN News and Press, Arvinas Inc. From 05/23/22

Arvinas announced decent data from ARV-110 in February. The market may have expected more. I will continue to hold. For further details see: Arvinas: Still Holding, Just Not Buying More

Even as macro concerns drove the major averages lower again in Monday's intraday action, earnings news remained a key catalyst for a handful of individual stocks. That list included Galaxy Digital (OTCPK:BRPHF), which lost more than a fifth of its value after the meltdown in the crypto market...

Arvinas (NASDAQ:ARVN -17.0%) stock falls after Wedbush downgraded rating to neutral from outperform and lowered PT to $48 from $98. Wedbush said it sees increased development challenges to breast cancer treatment, ARV-471, in light of recent study failures for oral SERDs amcenestrant (Sanofi)...

GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration PR Newswire SOMERVILLE, Mass. , May 9, 2022 /PRNewswire/ -- GNS Healthcare, the leader in the use of "Virtual Patients", Causal AI and simulation technology for biopharmaceutical comp...

Arvinas press release (NASDAQ:ARVN): Q1 GAAP EPS of -$1.20 misses by $0.28. Revenue of $24.2M (+336.8% Y/Y) misses by $1.31M. “It has been a very productive first quarter for Arvinas, as we prepare to initiate three planned pivotal clinical studies in the second half of 2022 for our tw...

NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate u...

NEW HAVEN, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Bank of America Securities ...

Arvinas press release (NASDAQ:ARVN): Q4 GAAP EPS of -$1.00 misses by $0.21. Revenue of $26.3M (+1095.5% Y/Y) beats by $11.22M. For further details see: Arvinas GAAP EPS of -$1.00 misses by $0.21, revenue of $26.3M beats by $11.22M

NEW HAVEN, Conn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2021 and pro...

– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA 50 rate and durable RECIST responses – – Data support the potential for an accelerated approval pathway in a mole...